Cargando…
Enhanced Detection of Landmark Minimal Residual Disease in Lung Cancer Using Cell-free DNA Fragmentomics
Currently, approximately 30%–55% of the patients with non–small cell lung cancer (NSCLC) develop recurrence due to minimal residual disease (MRD) after receiving surgical resection of the tumor. This study aims to develop an ultrasensitive and affordable fragmentomic assay for MRD detection in patie...
Autores principales: | Wang, Siwei, Xia, Zhijun, You, Jing, Gu, Xiaolan, Meng, Fanchen, Chen, Peng, Tang, Wanxiangfu, Bao, Hua, Zhang, Jingyuan, Wu, Xue, Shao, Yang, Wang, Jie, Zuo, Xianglin, Xu, Lin, Yin, Rong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10228550/ https://www.ncbi.nlm.nih.gov/pubmed/37377889 http://dx.doi.org/10.1158/2767-9764.CRC-22-0363 |
Ejemplares similares
-
Multidimensional Cell-Free DNA Fragmentomic Assay for Detection of Early-Stage Lung Cancer
por: Wang, Siwei, et al.
Publicado: (2022) -
Multi-dimensional fragmentomic assay for ultrasensitive early detection of colorectal advanced adenoma and adenocarcinoma
por: Ma, Xiaoji, et al.
Publicado: (2021) -
Letter to the Editor: An ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection
por: Bao, Hua, et al.
Publicado: (2022) -
Cell-Free DNA Fragmentomics in Liquid Biopsy
por: Ding, Spencer C., et al.
Publicado: (2022) -
Cell-Free DNA Fragmentomics: The Novel Promising Biomarker
por: Qi, Ting, et al.
Publicado: (2023)